{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:33:28Z","timestamp":1790836408773,"version":"4.1.0"},"reference-count":75,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2237336","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T11:35:10Z","timestamp":1689766510000},"page":"944-953","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Early access for innovative oncology medicines: a different story in each nation"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-8552","authenticated-orcid":false,"given":"Tara","family":"Cowling","sequence":"first","affiliation":[{"name":"Medlior Health Outcomes Research Ltd., Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7327-6898","authenticated-orcid":false,"given":"Ransi","family":"Nayakarathna","sequence":"additional","affiliation":[{"name":"Medlior Health Outcomes Research Ltd., Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Wills","sequence":"additional","affiliation":[{"name":"20Sense Corp., Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Tankala","sequence":"additional","affiliation":[{"name":"AbbVie, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Paul Roc","sequence":"additional","affiliation":[{"name":"AbbVie, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Barakat","sequence":"additional","affiliation":[{"name":"AbbVie, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_4_3_1","unstructured":"Cancer statistics at a glance; 2022. Available from: https:\/\/cancer.ca\/en\/research\/cancer-statistics\/cancer-statistics-at-a-glance"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4087"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(22)00090-1"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(22)00111-6"},{"key":"e_1_3_4_7_1","unstructured":"The global use of medicines 2022: outlook to 2026; 2022. Available from: iqviainstitute.org"},{"key":"e_1_3_4_8_1","unstructured":"Global oncology trends 2022: outlook to 2026; 2022. Available from: iqviainstitute.org"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00909"},{"key":"e_1_3_4_10_1","unstructured":"National Institute of Health and Care Excellence (NICE); 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.nice.org.uk\/"},{"key":"e_1_3_4_11_1","unstructured":"Haute Autorite de Sante (HAS); 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.has-sante.fr\/jcms\/pprd_2986129\/en\/home"},{"key":"e_1_3_4_12_1","unstructured":"Gemeinsamer Bundesausschuss: G-BA; 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.g-ba.de\/english\/"},{"key":"e_1_3_4_13_1","unstructured":"Early access and off-label use. Italian Medicines Agency; 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.aifa.gov.it\/en\/web\/guest\/accesso-precoce-uso-off-label"},{"key":"e_1_3_4_14_1","unstructured":"PBAC. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC); 2016 [cited 2022 Aug 5]. Available from: https:\/\/pbac.pbs.gov.au\/home.html"},{"key":"e_1_3_4_15_1","unstructured":"The Institut national d\u2019excellence en sant\u00e9 et en services sociaux: INESSS; 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.inesss.qc.ca\/en\/about-us\/about-the-institut.html"},{"key":"e_1_3_4_16_1","unstructured":"IQWIG. The Independent Institute for Quality and Efficiency in Health Care; 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.iqwig.de\/en\/"},{"key":"e_1_3_4_17_1","unstructured":"CADTH: Canadian Agency for Drugs and Technologies in Health; 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.cadth.ca\/"},{"key":"e_1_3_4_18_1","unstructured":"2017\u20132027 Quebec Life Sciences Strategy: innovation comes to life. Montreal: Numerique; 2017. Available from: https:\/\/numerique.banq.qc.ca\/patrimoine\/details\/52327\/2977378"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5507"},{"key":"e_1_3_4_20_1","unstructured":"NICE health technology evaluations: the manual London: National Institute for Health and Care Excellence (NICE); 2022."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.20.2630"},{"key":"e_1_3_4_22_1","unstructured":"Public summary document \u2013 March 2021 PBAC meeting: venetoclax; 2021."},{"key":"e_1_3_4_23_1","unstructured":"Increasing access to innovative medicines. Innovative Medicines Canada; 2022 [cited 2023 Jun 23]. Available from: https:\/\/innovativemedicines.ca\/wp-content\/uploads\/2022\/10\/20221007_FINAL_PreBudget_Consultation-1.pdf"},{"key":"e_1_3_4_24_1","unstructured":"Hoskyn S. IMC\u2019s explaining public reimbursement delays for new medicines for Canadian patients. Ottawa: Innovative Medicines Canada; 2020 [cited 2023 Jun 23]. Available from: https:\/\/innovativemedicines.ca\/wp-content\/uploads\/2020\/07\/CADTH-TTL-8.5x11-EN-Final.pdf"},{"key":"e_1_3_4_25_1","unstructured":"Managed access. London: National Institute for Health and Care Excellence (NICE); 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/managed-access"},{"key":"e_1_3_4_26_1","doi-asserted-by":"crossref","unstructured":"Bee C Hawksworth C Wakefield L et\u00a0al. What goes in must come out: an analysis of NICE recommendations for drugs exiting managed (early) access in England. Value in Health. 2022;25(7):S478.","DOI":"10.1016\/j.jval.2022.04.990"},{"key":"e_1_3_4_27_1","unstructured":"Real-World Evidence Registry: ISPOR; 2023 [cited 2023 Jun 23]. Available from: https:\/\/www.ispor.org\/strategic-initiatives\/real-world-evidence\/real-world-evidence-registry"},{"key":"e_1_3_4_28_1","unstructured":"The ASSESS Project Overview: the ASSESS Project; 2023 [cited 2023 Jun 23]. Available from: https:\/\/static1.squarespace.com\/static\/617739c64fac81568f019217\/t\/64763ee17f0eea47d6f912fe\/1685470957572\/The+ASSESS+Project+Overview.pdf"},{"key":"e_1_3_4_29_1","volume-title":"LEGGE 23 luglio 2021, n. 106","author":"Gazzetta Ufficiale Della Republica Italiana","year":"2021","unstructured":"Gazzetta Ufficiale Della Republica Italiana. LEGGE 23 luglio 2021, n. 106. Rome: Republica Italiana; 2021."},{"key":"e_1_3_4_30_1","unstructured":"Galafold \u2013 Maladie de Fabry Avis transmis au ministre en octobre 2018. Institut national d\u2019excellence en sant\u00e9 et en services sociaux (INESSS); 2018 [cited 2023 Mar 28]. Available from: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Inscription_medicaments\/Avis_au_ministre\/Novembre_2018\/Galafold_2018_10.pdf"},{"key":"e_1_3_4_31_1","unstructured":"Authorisation for early access to medicinal products: HAS assessment doctrine. French National Authority for Health; 2021."},{"key":"e_1_3_4_32_1","unstructured":"Acc\u00e8s pr\u00e9coce des m\u00e9dicaments: accompagnement des laboratoires; 2021."},{"key":"e_1_3_4_33_1","unstructured":"Beley L Vooren BV Bogaert P. New early access and off-label use rules in France Inside EU Life Sciences. Covington; 2021 [updated 2021 Jul 6; cited 2022 Aug 5]. Available from: https:\/\/www.insideeulifesciences.com\/2021\/07\/06\/new-early-access-and-off-label-use-rules-in-france\/"},{"key":"e_1_3_4_34_1","unstructured":"Rodwin M. What can the United States learn from pharmaceutical spending controls in France? The Commonwealth Fund; 2019 [cited 2022 Dec 5]. Available from: https:\/\/www.commonwealthfund.org\/publications\/issue-briefs\/2019\/nov\/what-can-united-states-learn-drug-spending-controls-france"},{"key":"e_1_3_4_35_1","unstructured":"\"Compassionate Use\" Programmes. Federal institute for drugs and medical devices (BfArM); 2022."},{"key":"e_1_3_4_36_1","unstructured":"Drug approval and early benefit assessment in Germany: IQWIG; 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.iqwig.de\/en\/presse\/in-the-focus\/new-drugs-approval-benefit-assessment-coverage\/1-drug-approval-and-early-benefit-assessment-in-germany\/"},{"key":"e_1_3_4_37_1","unstructured":"AIFA. Early access and off-label use. Italian Medicines Agency; 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.aifa.gov.it\/en\/web\/guest\/accesso-precoce-uso-off-label"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.1964791"},{"key":"e_1_3_4_39_1","unstructured":"Selletti S Putignano M Tiboni F. Pricing & reimbursement laws and regulations 2022. Italy; 2022."},{"key":"e_1_3_4_40_1","unstructured":"Dickson M Hurst J Jacobzone S. Survey of pharmacoeconomic assessment activity in eleven countries. OECD Health Working Papers; 2003."},{"key":"e_1_3_4_41_1","unstructured":"Fast track approval pathways. Australian Government Department of Health and Aged Care. Therapeutic Goods Administration; 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.tga.gov.au\/fast-track-approval-pathways"},{"key":"e_1_3_4_42_1","unstructured":"Provisional approval pathway: prescription medicines. Australian Government Department of Health and Aged Care - Therapeutic Goods Administration; 2018 [cited 2023 Mar 28]. Available from: https:\/\/www.tga.gov.au\/provisional-approval-pathway-prescription-medicines"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0633-6"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2018.032"},{"key":"e_1_3_4_45_1","unstructured":"Special Access Programme: Drugs: Government of Canada. Ottawa: Health Canada; 2022 [cited 2023 Mar 28]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/special-access\/drugs\/special-access-programme-drugs.html"},{"key":"e_1_3_4_46_1","unstructured":"Outcomes-based agreements: Canadian experience and perceptions; 2021. Available from: https:\/\/static1.squarespace.com\/static\/61d708f9587415184afa9452\/t\/62055c8e7508c21a4b4239f0\/1645542729885\/RWE%2BOBA%2BWorking%2BGroup_Canadian%2BOBA%2BSurvey%2BResults_Oct-12-2021.pdf"},{"key":"e_1_3_4_47_1","unstructured":"Hoskyn S. Explaining public reimbursement delays for new medicines for Canadian patients. Ottawa (ON); 2020."},{"key":"e_1_3_4_48_1","unstructured":"Sehgal C Commissiong G Miller M. Innovative medicines Canada: data analytics and members\u2019 economic footprint and impact in Canada; 2017."},{"key":"e_1_3_4_49_1","unstructured":"Birch A. Patient assisting programs: LinkedIn; 2022 [cited 2023 Mar 28]. Available from: https:\/\/www.linkedin.com\/posts\/alan-birch-85b6842b_patient-assistance-programspdf-activity-6927594368677638144-LTEV?utm_source=share&utm_medium=member_desktop"},{"key":"e_1_3_4_50_1","unstructured":"BC Cancer. Manufacturer patient assistance programs; 2022. Available from: http:\/\/www.bccancer.bc.ca\/systemic-therapy-site\/Documents\/Policy%20and%20Forms\/Patient%20assistance%20programs.pdf"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4856"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1824161"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0314"},{"key":"e_1_3_4_54_1","unstructured":"The Conference Board of Canada. Tomorrow can\u2019t wait; understanding the value of breakthrough cancer treatments for Canadians; 2022 [cited 2022 Oct 31]. Available from: https:\/\/www.conferenceboard.ca\/focus-areas\/health\/tomorrow-cant-wait"},{"key":"e_1_3_4_55_1","unstructured":"NHS. Thousands of patients to benefit as NHS marks 100th fast-tracked cancer drug. NHS.UK; 2022 [cited 2022 Sep 18]. Available from: https:\/\/www.england.nhs.uk\/2022\/07\/thousands-of-patients-to-benefit-as-nhs-marks-100th-fast-tracked-cancer-drug\/"},{"key":"e_1_3_4_56_1","unstructured":"NHS commercial framework for new medicines; 2022 [cited 2022 Aug 5]. Available from: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/02\/B1688-nhs-commercial-framework-for-new-medicines-june-22.pdf"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-5050-9"},{"key":"e_1_3_4_58_1","unstructured":"NICE. Technology appraisal data: appraisal recommendations; 2022 [cited 2022 Nov 16]. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/data\/appraisal-recommendations"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1648971"},{"key":"e_1_3_4_60_1","unstructured":"Government of France. Code de la s\u00e9curit\u00e9 sociale-version en vigueur du 07 juin 2018\u2009au 28 ao\u00fbt 2020; 2018 [cited 2023 Mar 28]. Available from: https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000037008543\/2018-06-07"},{"key":"e_1_3_4_61_1","unstructured":"Haute Autorite de Sante (HAS). D\u00e9cision n\u00b02013.0111\/DC\/SEESP du 18 septembre 2013 du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 relatif \u00e0 l\u2019impact significatif sur les d\u00e9penses de l\u2019assurance maladie d\u00e9clenchant l\u2019\u00e9valuation m\u00e9dico-\u00e9conomique des produits revendiquant une ASMR ou une ASA de niveaux I II ou III; 2013 [cited 2023 Mar 28]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2013-09\/c_2013_0111_definition_impact_significatif.pdf"},{"key":"e_1_3_4_62_1","unstructured":"Haute Autorite de Sante (HAS). D\u00e9cision n\u00b02022.0212\/DC\/SED\/SEM du 23 juin 2022 du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 relative \u00e0 l\u2019impact significatif sur les d\u00e9penses de l\u2019assurance maladie d\u00e9clenchant l\u2019\u00e9valuation m\u00e9dico-\u00e9conomique des produits de sant\u00e9 revendiquant une ASMR ou une ASA de niveaux I II ou III; 2022 [cited 2023 Mar 28]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2022-08\/decision_n2022.0212_dc_sed_sem_du_23_juin_2022_du_college_de_la_haute_autorite_de_sante_relative_a_limpact_significatif_sur_.pdf"},{"key":"e_1_3_4_63_1","unstructured":"HAS. Decision No. 2018.0233\/DC\/SEESP of 5 December 2018 of the College of the High Authority for Health amending Decision No. 2013.0111\/DC\/SEESP of 18 September 2013 on the significant impact on health insurance expenditure triggering the medico-economic evaluation of products claiming ASMR or ASA levels I II or III; 2018 [cited 2022 Oct 31]. Available from: https:\/\/www.has-sante.fr\/jcms\/c_2896885\/fr\/decision-n-2018-0233\/dc\/seesp-du-5-decembre-2018-du-college-de-la-haute-autorite-de-sante-modifiant-la-decision-n-2013-0111\/dc\/seesp-du-18-septembre-2013-relative-a-l-impact-significatif-sur-les-depenses-de-l-assurance-maladie-declenchant-l-evaluation-medico-economique-des-produits-revendiquant-une-asmr-ou-une-asa-de-niveaux-i-ii-ou-iii"},{"key":"e_1_3_4_64_1","unstructured":"Covington. New German government plans significant changes with impact on the healthcare life sciences and food sector; 2021 [cited 2022 Sep 19]. Available from: https:\/\/www.insideeulifesciences.com\/2021\/11\/29\/new-german-government-plans-significant-changes-with-impact-on-the-healthcare-life-sciences-and-food-sector\/"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2019.02.009"},{"key":"e_1_3_4_66_1","unstructured":"AIFA. Italian Medicines Agency. Authorisation of medicinal products; [cited 2022 Aug 5]. Available from: https:\/\/www.aifa.gov.it\/en\/web\/guest\/autorizzazione-dei-farmaci"},{"key":"e_1_3_4_67_1","unstructured":"AIFA. Economic evaluations; [cited 2022 Oct 31]. Available from: https:\/\/www.aifa.gov.it\/en\/valutazioni-economiche"},{"key":"e_1_3_4_68_1","unstructured":"Pharmaceutical Benefits Advisory Committee (PBAC). Public summary document \u2013 November 2021 PBAC meeting: gilteritinib; 2021 [cited 2023 Mar 28]. Available from: https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2021-11\/files\/gilteritinib-psd-nov-2021.pdf"},{"key":"e_1_3_4_69_1","unstructured":"Pharmaceutical Benefits Advisory Committee (PBAC). Public summary document \u2013 July 2021 PBAC meeting: Venetoclax; 2021 [cited 2023 Mar 28]. Available from: https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2021-07\/files\/venetoclax-psd-july-2021.pdf"},{"key":"e_1_3_4_70_1","unstructured":"CADTH. CADTH Programs and Services; 2022 [cited 2022 Oct 2]. Available from: https:\/\/www.cadth.ca\/programs-and-services"},{"key":"e_1_3_4_71_1","unstructured":"INAHTA. INESSS \u2013 Institit national d\u2019excellence en sante\u2019 et en services sociaux; 2022 [cited 2022 Oct 31]. Available from: https:\/\/www.inahta.org\/members\/inesss\/"},{"key":"e_1_3_4_72_1","unstructured":"NHS UK. NHS to offer new drug that halves the risk of cancer returning; 2021 [cited 2022 Sep 18]. Available from: https:\/\/www.england.nhs.uk\/2021\/05\/nhs-to-offer-new-drug-that-halves-the-risk-of-cancer-returning\/"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29020083"},{"key":"e_1_3_4_74_1","unstructured":"National Institute of Health and Care Excellence (NICE). Over 600 people set to benefit from innovative lung cancer treatment within the Cancer Drugs Fund; 2021 [cited 2022 Nov 21]. Available from: https:\/\/www.nice.org.uk\/news\/article\/over-600-people-set-to-benefit-from-innovative-lung-cancer-treatment-within-the-cancer-drugs-fund"},{"key":"e_1_3_4_75_1","unstructured":"Deloitte. A collaborative assessment of access to cancer medicines in Australia; 2017 [cited 2022 Sep 18]. Available from: https:\/\/www2.deloitte.com\/au\/en\/pages\/economics\/articles\/access-cancer-medicines-australia.html"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-018-0131-4"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2237336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:07:23Z","timestamp":1701943643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2237336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2237336"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2237336","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}